DK2329259T3 - Markører og fremgangsmåder til bedømmelse og behandling af ulcerativ colitis og beslægtede sygdomme under anvendelse af et 20-genpanel - Google Patents
Markører og fremgangsmåder til bedømmelse og behandling af ulcerativ colitis og beslægtede sygdomme under anvendelse af et 20-genpanel Download PDFInfo
- Publication number
- DK2329259T3 DK2329259T3 DK09810643.8T DK09810643T DK2329259T3 DK 2329259 T3 DK2329259 T3 DK 2329259T3 DK 09810643 T DK09810643 T DK 09810643T DK 2329259 T3 DK2329259 T3 DK 2329259T3
- Authority
- DK
- Denmark
- Prior art keywords
- sample
- nucleic acid
- patient
- tnfα antibody
- ulcerative colitis
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (15)
1. Fremgangsmåde til forudsige egnetheden af behandling med målterapi til en gastrointestinal-beslægtet sygdom i et individ, hvor individet er en patient tilvejebringe prøven før administration af terapien, og hvor terapien er et anti-TNFa-antistof, omfattende: a) tilvejebringe en prøve af nukleinsyrer fra et prøvemateriale opnået fra individet; b) bringe prøven i kontakt med et panel af nukleinsyresegmenter bestående af SEQ ID NO: 1-20 for at påvise niveauerne af panelsegmenterne; c) bedømme prøven mod en referencestandard fra en responder til terapien for at bestemme de relative ekspressionsniveauer fra alle medlemmer fra gruppen bestående af nukleotidsekvenser svarende til SEQ ID NO: 1-20 sammenlignet med referencestandarden; og d) korrelere de relative ekspressionsniveauer fra prøven og referencestandarden med egnetheden af behandling med mål-terapien for den gastrointestinalt-beslægtede forstyrrelse.
2. Fremgangsmåden ifølge krav 1, hvor anti-TNFa-antistoffet er infliximab.
3. Fremgangsmåden ifølge krav 2, hvor den gastrointestinalt-beslægtede forstyrrelse er ulcerativ colitis.
4. Fremgangsmåden ifølge krav 3, hvor referencestandarden er fra en colonbiopsi fra en responder til målterapien.
5. Fremgangsmåden ifølge krav 1, hvor panelet er et array af nukleinsyresegmenter.
6. Fremgangsmåden ifølge krav 1, hvor prøven omfatter en colonbiopsiprøve eller perifere blodceller.
7. Fremgangsmåde ifølge krav 1, der er en array-baseret testfremgangsmåde til at forudsige egnetheden af behandling med målterapi til en gastrointestinal-beslægtet forstyrrelse hos en patient, omfattende: a) fremstille en blanding af nukleinsyrer fra et prøvemateriale opnået fra patienten; b) mærke disse nukleinsyreprøver med en påviselig markør for at danne en prøve; c) bringe prøven i kontakt med et array omfattende en flerhed af nukleinsyresegmenter, hvor hvert nukleinsyresegment er er immobiliseret til en diskret og kendt adresse på en substratoverflade af arrayet, hvor et gastrointestinal-beslægtet genpanel bestående af nukleotidsekvenser svarende til SEQ ID NO: 1-20 identificeres som træk af arrayet ved adresse, og hvor arrayet yderligere omfatter mindst én kalibreringsnukleinsyre ved en kendt adresse på substratet; d) bestemme bindingsgraden af nukleinsyreprøverne til nukleinsyresegmenterne; og e) sammenligne bindingsgraden med referencestandarden for at muliggøre bedømmelsen af egnetheden for behandling.
8. Fremgangsmåden ifølge krav 7, hvor sammenligningstrinnet omfatter at bedømme prøven mod en referencestandard for at bestemme styrkeændringen i mængderne af nukleotidsekvenser svarende til SEQ ID NOS: 1-20.
9. Fremgangsmåden ifølge krav 8, hvor: i) den gastrointestinalt-beslægtede forstyrrelse er ulcerativ colitis og det gastrointestinal-beslægtede genpanel er et ulcerativ colitis-beslægtet genpanel; ii) mål-terapien er et anti-TNFa-antistof; iii) prøven er fra en colonbiopsi fra en patient valgt fra gruppen bestående af patienter der er mistænkt for at have ulcerativ colitis og patienter diagnosticeret med ulcerativ colitis der ikke undergår behandling; iv) prøven er fra en kilde valgt fra gruppen bestående af en patient der tilvejebringer prøven før administration af terapi, en patient havende en lignende sygdom eller tilstand behandlet med placebo, og en prøve fra en biobank; v) prøven omfatter en colon-biopsiprøve eller perifere blodceller; eller vi) sammenligne graden af bindingstrinnet yderligere omfatter en stringent test af sammenlignelighed af trækintensitetsændringer af arrayet af det ulcerative colitis-beslægtede genpanel.
10. Reagens til testning af egnetheden af et anti-TNFa-antistof til en gastrointestinal-beslægtet forstyrrelse i en celle eller individ før administration af anti-TNFa-antistoffet, omfattende oligonukleotider omfattende mindst 15 nukleotider omfattende eller komplementær med en nukleotidsekvens for hver af nukleotidsekvenserne svarende til SEQ ID NOS: 1-20,
11. Reagenset ifølge krav 10, hvor den gastrointestinalt-beslægtede forstyrrelse er ulcerativ colitis og eventuelt hvor anti-TNFa-antistoffet er infliximab.
12. Fremgangsmåde til testning af egnetheden af et anti-TNFa-antistof til en gastrointestinal-beslægtet forstyrrelse i en patientprøve fra en patient før administration af anti-TNFa-antistoffet, omfattende at bringe patientprøven i kontakt med reagenset ifølge krav 10 og sammenligne niveauerne på mindst en del af hver af generne fra nukleotidsekvenser svarende til SEQ ID NO: 1-20 med en referencestandard, hvor referencestandarden er fra en responder til anti-TNFa-antistoffet.
13. Fremgangsmåden ifølge krav 12: i) hvor testningen foretages ved RT-PCR eller ii) hvor anti-TNFa-antistoffet er infliximab.
14. Fremgangsmåde til testning af effektiviteten af et anti-TNFa-antistof for ulcerativ colitis, omfattende: a) at bringe en prøve fra en patient der bliver behandlet for ulcerativ colitis i kontakt med reagenset ifølge krav 10; b) måle niveauerne fra de 20 medlemmer; og c) korrelere niveauerne fra de 20 medlemmer med effektiviteten af anti-TNFa-antistoffet ved at sammenligne niveauerne med niveauer i en referencestandard, hvor referencestandarden er fra en responder til anti-TNFa-antistoffet.
15. Fremgangsmåden ifølge krav 14, hvor anti-TNFa-antistoffet er infliximab.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9296608P | 2008-08-29 | 2008-08-29 | |
PCT/US2009/055323 WO2010025340A2 (en) | 2008-08-29 | 2009-08-28 | Markers and methods for assessing and treating ulcerative colitis and related disorders using a 20 gene panel |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2329259T3 true DK2329259T3 (da) | 2016-05-09 |
Family
ID=41722298
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK09810643.8T DK2329259T3 (da) | 2008-08-29 | 2009-08-28 | Markører og fremgangsmåder til bedømmelse og behandling af ulcerativ colitis og beslægtede sygdomme under anvendelse af et 20-genpanel |
Country Status (12)
Country | Link |
---|---|
US (1) | US20100069256A1 (da) |
EP (1) | EP2329259B1 (da) |
JP (1) | JP5586607B2 (da) |
CN (1) | CN102165315B (da) |
AU (1) | AU2009285644B2 (da) |
BR (1) | BRPI0917379A2 (da) |
CA (1) | CA2734519C (da) |
DK (1) | DK2329259T3 (da) |
ES (1) | ES2581774T3 (da) |
IL (1) | IL211154A0 (da) |
RU (1) | RU2011111748A (da) |
WO (1) | WO2010025340A2 (da) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7943310B2 (en) * | 2006-08-30 | 2011-05-17 | Centocor Ortho Biotech Inc. | Methods for assessing response to therapy in subjects having ulcerative colitis |
JP2014517279A (ja) | 2011-05-10 | 2014-07-17 | ネステク ソシエテ アノニム | 個別治療管理のための疾患活動性プロファイリングの方法 |
MX2017004742A (es) * | 2014-10-20 | 2017-07-20 | Nestec Sa | Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos. |
WO2016092045A1 (en) * | 2014-12-11 | 2016-06-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and kits for predicting medically refractory acute severe colitis |
GB2547406A (en) * | 2015-11-20 | 2017-08-23 | Folkersen Lasse | Apparatus and methods of using of biomarkers for predicting TNF-inhibitor response |
US11549146B2 (en) | 2016-05-20 | 2023-01-10 | Cedars-Sinai Medical Center | Diagnosis of inflammatory bowel disease based on genes |
WO2017216206A1 (en) * | 2016-06-14 | 2017-12-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting acute severe colitis treatment response |
AU2018277256A1 (en) | 2017-05-31 | 2020-01-30 | Prometheus Biosciences, Inc. | Methods for assessing mucosal healing in Crohn's disease patients |
EP3821246A4 (en) * | 2018-07-15 | 2022-06-22 | Rambam Med-Tech Ltd. | DETERMINATION OF RESPONSE TO AN INFLAMMATORY TREATMENT |
WO2020082011A1 (en) * | 2018-10-19 | 2020-04-23 | Children's Hospital Medical Center | Use of mucosal transcriptomes for assessing severity of ulcerative colitis and responsiveness to treatment |
EA202191354A1 (ru) * | 2018-11-15 | 2021-08-11 | Янссен Байотек, Инк. | Способы и композиции для прогнозирования ответа на терапию воспалительного заболевания кишечника |
CN114015689B (zh) * | 2021-10-26 | 2024-06-07 | 江苏大学 | 一种特异性抑制GOS2基因表达的shRNA序列及其应用 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US5721098A (en) | 1986-01-16 | 1998-02-24 | The Regents Of The University Of California | Comparative genomic hybridization |
US5525464A (en) | 1987-04-01 | 1996-06-11 | Hyseq, Inc. | Method of sequencing by hybridization of oligonucleotide probes |
GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
US6054270A (en) | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
US5527681A (en) | 1989-06-07 | 1996-06-18 | Affymax Technologies N.V. | Immobilized molecular synthesis of systematically substituted compounds |
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
WO1993018186A1 (en) | 1992-03-04 | 1993-09-16 | The Regents Of The University Of California | Comparative genomic hybridization (cgh) |
US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
US6156501A (en) | 1993-10-26 | 2000-12-05 | Affymetrix, Inc. | Arrays of modified nucleic acid probes and methods of use |
US6045996A (en) | 1993-10-26 | 2000-04-04 | Affymetrix, Inc. | Hybridization assays on oligonucleotide arrays |
ATE214633T1 (de) | 1993-10-28 | 2002-04-15 | Houston Advanced Res Ct | Mikrofabriziertes poröses durchflussgerät |
GB9401833D0 (en) | 1994-02-01 | 1994-03-30 | Isis Innovation | Method for discovering ligands |
US5556752A (en) | 1994-10-24 | 1996-09-17 | Affymetrix, Inc. | Surface-bound, unimolecular, double-stranded DNA |
US5830645A (en) | 1994-12-09 | 1998-11-03 | The Regents Of The University Of California | Comparative fluorescence hybridization to nucleic acid arrays |
US5959098A (en) | 1996-04-17 | 1999-09-28 | Affymetrix, Inc. | Substrate preparation process |
US5856174A (en) | 1995-06-29 | 1999-01-05 | Affymetrix, Inc. | Integrated nucleic acid diagnostic device |
US5723320A (en) | 1995-08-29 | 1998-03-03 | Dehlinger; Peter J. | Position-addressable polynucleotide arrays |
US5843655A (en) | 1995-09-18 | 1998-12-01 | Affymetrix, Inc. | Methods for testing oligonucleotide arrays |
US6022963A (en) | 1995-12-15 | 2000-02-08 | Affymetrix, Inc. | Synthesis of oligonucleotide arrays using photocleavable protecting groups |
EP0880598A4 (en) | 1996-01-23 | 2005-02-23 | Affymetrix Inc | RAPID EVALUATION OF NUCLEIC ACID ABUNDANCE DIFFERENCE, WITH A HIGH-DENSITY OLIGONUCLEOTIDE SYSTEM |
US6013440A (en) | 1996-03-11 | 2000-01-11 | Affymetrix, Inc. | Nucleic acid affinity columns |
US6057100A (en) | 1996-06-07 | 2000-05-02 | Eos Biotechnology, Inc. | Oligonucleotide arrays |
ATE234674T1 (de) | 1996-11-14 | 2003-04-15 | Affymetrix Inc | Chemische amplifizierung zur synthese von musterordnungen |
JP2001514906A (ja) | 1997-08-15 | 2001-09-18 | ハイセック,インコーポレーテッド | 核酸種を検出または定量するための方法および組成物 |
US6197503B1 (en) | 1997-11-26 | 2001-03-06 | Ut-Battelle, Llc | Integrated circuit biochip microsystem containing lens |
US6087102A (en) | 1998-01-07 | 2000-07-11 | Clontech Laboratories, Inc. | Polymeric arrays and methods for their use in binding assays |
US6087103A (en) | 1998-03-04 | 2000-07-11 | Lifespan Biosciences, Inc. | Tagged ligand arrays for identifying target-ligand interactions |
IL138668A0 (en) | 1998-04-03 | 2001-10-31 | Phylos Inc | Addressable protein arrays |
US6048695A (en) | 1998-05-04 | 2000-04-11 | Baylor College Of Medicine | Chemically modified nucleic acids and methods for coupling nucleic acids to solid support |
US6093370A (en) | 1998-06-11 | 2000-07-25 | Hitachi, Ltd. | Polynucleotide separation method and apparatus therefor |
US6087112A (en) | 1998-12-30 | 2000-07-11 | Oligos Etc. Inc. | Arrays with modified oligonucleotide and polynucleotide compositions |
US6174684B1 (en) | 1999-08-11 | 2001-01-16 | Trustees Of The University Of Pennsylvania | CYP3A4 NFSE variant and methods of use therefore |
AU2001255518A1 (en) | 2000-06-07 | 2001-12-17 | Baylor College Of Medicine | Compositions and methods for array-based nucleic acid hybridization |
US20040077020A1 (en) * | 2001-11-30 | 2004-04-22 | Mannick Elizabeth E. | Diagnostic microarray for inflammatory bowel disease, crohn's disease and ulcerative colitis |
EP1545608A4 (en) | 2002-06-28 | 2006-09-13 | Centocor Inc | CH1-DELETED MAMMED MUICETIC BODIES, COMPOSITIONS, METHODS AND APPLICATIONS |
WO2006048291A2 (en) * | 2004-11-03 | 2006-05-11 | Almac Diagnostics Limited | Transcriptome microarray technology and methods of using the same |
WO2007103823A2 (en) * | 2006-03-03 | 2007-09-13 | University Of Southern California | Genetic markers for predicting disease and treatment outcome |
US7943310B2 (en) * | 2006-08-30 | 2011-05-17 | Centocor Ortho Biotech Inc. | Methods for assessing response to therapy in subjects having ulcerative colitis |
EP2148943B1 (en) * | 2007-04-30 | 2016-10-05 | Janssen Biotech, Inc. | Methods for assessing and treating ulcerative colitis and related disorders using a 19 gene panel |
NZ590988A (en) * | 2008-08-25 | 2012-08-31 | Janssen Biotech Inc | Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders |
-
2009
- 2009-08-28 CN CN200980134148.1A patent/CN102165315B/zh active Active
- 2009-08-28 DK DK09810643.8T patent/DK2329259T3/da active
- 2009-08-28 AU AU2009285644A patent/AU2009285644B2/en active Active
- 2009-08-28 CA CA2734519A patent/CA2734519C/en active Active
- 2009-08-28 EP EP09810643.8A patent/EP2329259B1/en active Active
- 2009-08-28 JP JP2011525223A patent/JP5586607B2/ja active Active
- 2009-08-28 ES ES09810643.8T patent/ES2581774T3/es active Active
- 2009-08-28 WO PCT/US2009/055323 patent/WO2010025340A2/en active Application Filing
- 2009-08-28 BR BRPI0917379A patent/BRPI0917379A2/pt not_active Application Discontinuation
- 2009-08-28 RU RU2011111748/15A patent/RU2011111748A/ru unknown
- 2009-08-31 US US12/550,703 patent/US20100069256A1/en not_active Abandoned
-
2011
- 2011-02-10 IL IL211154A patent/IL211154A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
WO2010025340A2 (en) | 2010-03-04 |
AU2009285644B2 (en) | 2015-08-20 |
CN102165315B (zh) | 2014-06-18 |
JP2012501452A (ja) | 2012-01-19 |
AU2009285644A1 (en) | 2010-03-04 |
EP2329259A2 (en) | 2011-06-08 |
EP2329259A4 (en) | 2012-05-16 |
IL211154A0 (en) | 2011-04-28 |
CA2734519A1 (en) | 2010-03-04 |
WO2010025340A3 (en) | 2010-04-22 |
JP5586607B2 (ja) | 2014-09-10 |
EP2329259B1 (en) | 2016-04-20 |
CN102165315A (zh) | 2011-08-24 |
BRPI0917379A2 (pt) | 2015-11-17 |
US20100069256A1 (en) | 2010-03-18 |
CA2734519C (en) | 2018-11-13 |
ES2581774T3 (es) | 2016-09-07 |
RU2011111748A (ru) | 2012-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2329259T3 (da) | Markører og fremgangsmåder til bedømmelse og behandling af ulcerativ colitis og beslægtede sygdomme under anvendelse af et 20-genpanel | |
EP2326731B1 (en) | Biomarkers for anti-tnf treatment in ulcerative colitis and related disorders | |
US7943310B2 (en) | Methods for assessing response to therapy in subjects having ulcerative colitis | |
US20080293582A1 (en) | Markers and Methods for Assessing and Treating Ulcerative Colitis and Related Disorders Using a 43 Gene Panel | |
US20090270480A1 (en) | Markers and Methods for Assessing and Treating Psoriasis and Related Disorders | |
EP2074230A2 (en) | Compositions and methods for treating and diagnosing irritable bowel syndrome | |
US20140011704A1 (en) | Markers and Methods for Assessing and Treating Crohn's Disease and Related Disorders | |
US20100331209A1 (en) | Markers and methods for assessing and treating severe or persistant asthma and tnf related disorders | |
EP2148943B1 (en) | Methods for assessing and treating ulcerative colitis and related disorders using a 19 gene panel |